Doull v. Foster

Massachusetts Supreme Judicial Court·Decided February 26, 2021·No. SJC 12921·Published

Opinion

NOTICE: All slip opinions and orders are subject to formal revision and are superseded by the advance sheets and bound volumes of the Official Reports. If you find a typographical error or other formal error, please notify the Reporter of Decisions, Supreme Judicial Court, John Adams Courthouse, 1 Pemberton Square, Suite 2500, Boston, MA, 02108-1750; (617) 557- 1030; SJCReporter@sjc.state.ma.us

SJC-12921 SETH DOULL1 & another2 vs. ANNA C. FOSTER & another.3

Franklin. October 5, 2020. - February 26, 2021.

Present: Budd, C.J., Gaziano, Lowy, Cypher, & Kafker, JJ.

Negligence, Medical malpractice, Causation, Standard of care.

Medical Malpractice, Standard of care, Consent to medical treatment. Practice, Civil, Instructions to jury, Amendment of complaint, Interrogation of jurors.

Civil action commenced in the Superior Court Department on May 28, 2014.

The case was tried before Mary-Lou Rup, J., and a motion for a new trial was considered by her.

The Supreme Judicial Court on its own initiative transferred the case from the Appeals Court.

Krzysztof G. Sobczak for the plaintiffs.

Tory A. Weigand for the defendants.

Jennifer A. Creedon & Stephanie M. Gazda, for Massachusetts Defense Lawyers Association, amicus curiae, submitted a brief.

1 Individually, as personal representative of the estate of Laura Doull, and as next friend of Troy Doull.

2 Megan Doull.

3 Robert J. Miller.

Brendan G. Carney, Thomas R. Murphy, Kevin J. Powers, & Elizabeth N. Mulvey, for Massachusetts Academy of Trial Attorneys, amicus curiae, submitted a brief.

KAFKER, J. Causation has been a continually contested concept in tort law, confounding courts, commentators, and practitioners. In this medical malpractice case, we are asked once again to clarify our case law on causation, along with a series of other issues that are more readily decided. Specifically, we examine the use of two competing causation standards: the traditional but-for causation standard and the alternative substantial contributing factor standard. After careful review, we conclude that the traditional but-for factual causation standard is the appropriate standard to be employed in most cases, including those involving multiple alleged causes. This is the approach recommended by the Restatement (Third) of Torts: Liability for Physical and Emotional Harm (2010) (Restatement [Third]). In doing so, we conclude that the substantial factor test is unnecessarily confusing and discontinue its use, even in multiple sufficient cause cases. Because the jury in this case were instructed using traditional but-for causation principles, the instructions were proper. We

also reject all of the plaintiffs' other claims on appeal and affirm the order denying a new trial.4 1. Background. We summarize the facts that could have been found by the jury, reserving certain facts for later discussion.

a. Facts. Between 2008 and 2011, Laura Doull was a patient of Anna C. Foster, a nurse practitioner, and her supervisor, Dr. Richard J. Miller (collectively, the defendants). Miller, an internist, owned the medical practice where Doull was a patient.

In August 2008, Doull had an appointment with Foster to seek advice regarding perimenopause-related symptoms. Foster prescribed Doull a topically applied, naturally derived progesterone cream to treat the symptoms.5 Foster admitted that she did not document any conversation that she had with Doull about the risks and benefits of, or the alternatives to, the progesterone cream, but she did testify that they discussed alternatives to it. However, Foster stated that she did not

4 We acknowledge the amicus briefs submitted by the Massachusetts Academy of Trial Attorneys and the Massachusetts Defense Lawyers Association.

5 Progesterone is a hormone that humans naturally produce.

Supplementing the progesterone that the human body produces is a form of hormone replacement therapy typically used to treat menopause- or perimenopause-related symptoms. Progesterone supplements come in both synthetic and naturally derived forms.

discuss the possibility with Doull that the progesterone cream could cause blood clots because she did not consider this to be a risk. Doull continued to use the progesterone cream through the spring of 2011.

Earlier that spring, Doull had visited Miller's practice on three separate occasions to complain about shortness of breath. Doull met with Foster on each visit, and Foster performed a physical examination of Doull each time. Doull had a history of asthma and allergies. At the spring 2011 visits, Foster diagnosed Doull's shortness of breath as a symptom of some combination of these long-standing conditions. Miller did not examine Doull during any of these visits.

In May 2011, Doull had a "seizure-like event" and was transported to the hospital. At the hospital, she was diagnosed with a pulmonary embolism, a condition where blood clots or other substances block portions of the pulmonary arteries in the lungs. A pulmonary embolism may cause shortness of breath as well as chronic thromboembolic pulmonary hypertension (CTEPH), a rare disease where pressure in the pulmonary artery increases and causes the heart to fail. Indeed, that May, Doull was diagnosed with CTEPH. A lung scan revealed that blood clots in Doull's lungs were chronic.

In November 2011, Doull underwent surgery in an attempt to remove the blockage from her lungs, but the procedure proved

unsuccessful. After the surgery, Doull was prescribed various medications to treat the pulmonary hypertension that had resulted from her CTEPH. None of these medications abated the disease. In 2015, Doull died from complications arising from CTEPH. She was forty-three years old.

b. Procedural history. Prior to her death, Doull and various family members (collectively, the plaintiffs) commenced this suit against the defendants, claiming negligence, failure to obtain informed consent, and loss of consortium.6 Four months before trial, the plaintiffs moved to amend their complaint to include the manufacturer of the progesterone cream, Women's International Compounding Inc. (WIC), as a defendant. The trial judge denied the plaintiffs' motion.

At trial, the plaintiffs argued that Miller and Foster failed to obtain informed consent from Doull concerning the progesterone cream's risks and alternatives, that Foster failed to diagnose Doull's pulmonary embolism during the spring 2011 visits, and that Miller failed to supervise Foster adequately during all relevant times.

To support these claims, Dr. Paul Genecin, a primary care internal medicine physician and the plaintiffs' expert witness, testified that natural progesterone was not any safer than

6 Doull's estate continued to prosecute the claims after her death, amending the complaint to add a wrongful death claim.

synthetic derivations of the hormone, and that the cream likely caused Doull to develop blood clots. Genecin also testified that Foster had failed to investigate adequately Doull's shortness of breath complaints during the spring 2011 visits. He testified that diagnosis of Doull's pulmonary embolism during the spring of 2011 could have prevented the onset of CTEPH, and that Miller's failure to supervise Foster's actions constituted a breach of the duty of care.

Dr. Nicholas S. Hill, a pulmonologist and an expert for the defense, testified that there was "no evidence anywhere that indicates that progesterone cream applied to the skin increases the risk of clotting." Hill also disagreed with Genecin's assessment that Doull's CTEPH would have been preventable had Foster diagnosed it during the spring 2011 visits. Specifically, Hill testified that by the time Doull was diagnosed with CTEPH in May 2011, the disease "had been going on for a long time, probably months at least." According to Hill, the chronic nature of Doull's blood clots meant that her outcome would have remained the same had Foster diagnosed her with the disease during the spring of 2011.

Free access — add to your briefcase to read the full text and ask questions with AI

Doull v. Foster, (Mass. 2021).

Doull v. Foster (Doull v. Foster) — published by Counsel Stack Legal Research, free access to 12M+ legal documents.

Related

Price Waterhouse v. Hopkins
490 U.S. 228 (Supreme Court, 1989)
June v. Union Carbide Corp.
577 F.3d 1234 (Tenth Circuit, 2009)
Mitchell v. Gonzales
819 P.2d 872 (California Supreme Court, 1991)
Thompson v. Kaczinski
774 N.W.2d 829 (Supreme Court of Iowa, 2009)
Tritsch v. Boston Edison Co.
293 N.E.2d 264 (Massachusetts Supreme Judicial Court, 1973)
O'CONNOR v. Raymark Industries, Inc.
518 N.E.2d 510 (Massachusetts Supreme Judicial Court, 1988)
Collins v. Baron
467 N.E.2d 171 (Massachusetts Supreme Judicial Court, 1984)
Allen v. Batchelder
459 N.E.2d 129 (Massachusetts Appeals Court, 1984)
Mathis v. Massachusetts Electric Co.
565 N.E.2d 1180 (Massachusetts Supreme Judicial Court, 1991)
Welch v. Keene Corp.
575 N.E.2d 766 (Massachusetts Appeals Court, 1991)
Avery v. Steele
608 N.E.2d 1014 (Massachusetts Supreme Judicial Court, 1993)
Boothby v. Texon, Inc.
608 N.E.2d 1028 (Massachusetts Supreme Judicial Court, 1993)
Michnik-Zilberman v. Gordon's Liquor, Inc.
453 N.E.2d 430 (Massachusetts Supreme Judicial Court, 1983)
Bernier v. Boston Edison Co.
403 N.E.2d 391 (Massachusetts Supreme Judicial Court, 1980)
Castellucci v. United States Fidelity and Guaranty Co.
361 N.E.2d 1264 (Massachusetts Supreme Judicial Court, 1977)
Mullins v. Pine Manor College
449 N.E.2d 331 (Massachusetts Supreme Judicial Court, 1983)
Franklin v. Albert
411 N.E.2d 458 (Massachusetts Supreme Judicial Court, 1980)
Falvey v. Hamelburg
198 N.E.2d 400 (Massachusetts Supreme Judicial Court, 1964)
Pfeiffer v. Salas
271 N.E.2d 750 (Massachusetts Supreme Judicial Court, 1971)
Callahan v. Cardinal Glennon Hospital
863 S.W.2d 852 (Supreme Court of Missouri, 1993)